{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Apoptosis", "Cancer", "Cell death", "Clinical efficacy", "Epigenetic pathways", "Human and disease", "Medicine", "Oncology"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "39021957", "DateRevised": {"Year": "2024", "Month": "07", "Day": "19"}, "Article": {"Language": ["eng"], "ELocationID": ["e33052", "10.1016/j.heliyon.2024.e33052"], "ArticleDate": [{"Year": "2024", "Month": "06", "Day": "18"}], "Journal": {"ISSN": "2405-8440", "JournalIssue": {"Volume": "10", "Issue": "12", "PubDate": {"Year": "2024", "Month": "Jun", "Day": "30"}}, "Title": "Heliyon", "ISOAbbreviation": "Heliyon"}, "ArticleTitle": "Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat.", "Pagination": {"StartPage": "e33052", "MedlinePgn": "e33052"}, "Abstract": {"AbstractText": ["The Food and Drug Administration (FDA) has approved vorinostat, also called Zolinza\u00ae, for its effectiveness in fighting cancer. This drug is a suberoyl-anilide hydroxamic acid belonging to the class of histone deacetylase inhibitors (HDACis). Its HDAC inhibitory potential allows it to accumulate acetylated histones. This, in turn, can restore normal gene expression in cancer cells and activate multiple signaling pathways. Experiments have proven that vorinostat induces histone acetylation and cytotoxicity in many cancer cell lines, increases the level of p21\u00a0cell cycle proteins, and enhances pro-apoptotic factors while decreasing anti-apoptotic factors. Additionally, it regulates the immune response by up-regulating programmed death-ligand 1 (PD-L1) and interferon gamma receptor 1 (IFN-\u03b3R1) expression, and can impact proteasome and/or aggresome degradation, endoplasmic reticulum function, cell cycle arrest, apoptosis, tumor microenvironment remodeling, and angiogenesis inhibition. In this study, we sought to elucidate the precise molecular mechanism by which Vorinostat inhibits HDACs. A deeper understanding of these mechanisms could improve our understanding of cancer cell abnormalities and provide new therapeutic possibilities for cancer treatment."], "CopyrightInformation": "\u00a9 2024 The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "High Institute of Nursing Professions and Health Techniques of Tetouan, Tetouan, Morocco."}], "LastName": "El Omari", "ForeName": "Nasreddine", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box 114, Postal Code 45142, Jazan, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal and Aromatic Plants Research Institute, National Center for Research, P.O. Box: 2424, Khartoum, 11111, Sudan."}], "LastName": "Khalid", "ForeName": "Asaad", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Practice Research Unit, Clinical Pharmacy Department, Faculty of Pharmacy, Jazan University, Jazan, Saudi Arabia."}], "LastName": "Makeen", "ForeName": "Hafiz A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box 114, Postal Code 45142, Jazan, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, P.O. Box 114, Postal Code 45142, Jazan, Saudi Arabia."}], "LastName": "Alhazmi", "ForeName": "Hassan A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, P.O. Box 114, Postal Code 45142, Jazan, Saudi Arabia."}], "LastName": "Albratty", "ForeName": "Mohammed", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box 114, Postal Code 45142, Jazan, Saudi Arabia."}, {"Identifier": [], "Affiliation": "School of Health Sciences, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India."}], "LastName": "Mohan", "ForeName": "Syam", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, KPJ Healthcare University, Nilai, Malaysia."}], "LastName": "Tan", "ForeName": "Ching Siang", "Initials": "CS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medical and Life Sciences, Sunway University, Sunway City, Malaysia."}], "LastName": "Ming", "ForeName": "Long Chiau", "Initials": "LC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medical and Life Sciences, Sunway University, Sunway City, Malaysia."}], "LastName": "Chook", "ForeName": "Jack Bee", "Initials": "JB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat, 10106, Morocco."}], "LastName": "Bouyahya", "ForeName": "Abdelhakim", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Heliyon", "NlmUniqueID": "101672560", "ISSNLinking": "2405-8440"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Hajam Y.A., Rani R., Ganie S.Y., Sheikh T.A., Javaid D., Qadri S.S., Pramodh S., Alsulimani A., Alkhanani M.F., Harakeh S., Hussain A., Haque S., Reshi M.S. Oxidative stress in human pathology and aging: molecular mechanisms and perspectives. Cells. 2022;11:552. doi: 10.3390/cells11030552.", "ArticleIdList": ["10.3390/cells11030552", "PMC8833991", "35159361"]}, {"Citation": "Subramaniam D., Thombre R., Dhar A., Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front. Oncol. 2014;4 doi: 10.3389/fonc.2014.00080.", "ArticleIdList": ["10.3389/fonc.2014.00080", "PMC4013461", "24822169"]}, {"Citation": "Kedhari Sundaram M., Haque S., Somvanshi P., Bhardwaj T., Hussain A. Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways. 3 Biotech. 2020;10:484. doi: 10.1007/s13205-020-02473-1.", "ArticleIdList": ["10.1007/s13205-020-02473-1", "PMC7584697", "33117625"]}, {"Citation": "Al-Griw M.A., Alshibani Z.O., Alghazeer R., Elhensheri M., Tabagh R.M., Eskandrani A.A., Alansari W.S., Habibulla M.M., Shamlan G. Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice. Sci. Rep. 2022;12 doi: 10.1038/s41598-022-12937-4.", "ArticleIdList": ["10.1038/s41598-022-12937-4", "PMC9205966", "35715448"]}, {"Citation": "Bouyahya A., Mechchate H., Oumeslakht L., Zeouk I., Aboulaghras S., Balahbib A., Zengin G., Kamal M.A., Gallo M., Montesano D. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022;12:367.", "ArticleIdList": ["PMC8945214", "35327559"]}, {"Citation": "Bouyahya A., El Hachlafi N., Aanniz T., Bourais I., Mechchate H., Benali T., Shariati M.A., Burkov P., Lorenzo J.M., Wilairatana P. Natural bioactive compounds targeting histone deacetylases in human cancers: recent updates. Molecules. 2022;27:2568.", "ArticleIdList": ["PMC9027183", "35458763"]}, {"Citation": "Mandumpala J.J., Baby S., Tom A.A., Godugu C., Shankaraiah N. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: epigenetic mnemonics. Life Sci. 2022", "ArticleIdList": ["35031259"]}, {"Citation": "Neganova M.E., Klochkov S.G., Aleksandrova Y.R., Aliev G. Semin. Cancer Biol. Elsevier; 2022. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress; pp. 452\u2013471.", "ArticleIdList": ["32814115"]}, {"Citation": "Borcoman E., Kamal M., Marret G., Dupain C., Castel-Ajgal Z., Le Tourneau C. HDAC inhibition to prime immune checkpoint inhibitors. Cancers. 2022;14:66.", "ArticleIdList": ["PMC8750966", "35008230"]}, {"Citation": "Hai R., Yang D., Zheng F., Wang W., Han X., Bode A.M., Luo X. The emerging roles of HDACs and their therapeutic implications in cancer. Eur. J. Pharmacol. 2022", "ArticleIdList": ["35988787"]}, {"Citation": "Mina\u0159\u00edk L., Pimkov\u00e1 K., Kokavec J., Schaffartzikov\u00e1 A., Vellieux F., Kulvait V., Daumov\u00e1 L., Dusilkov\u00e1 N., Jon\u00e1\u0161ov\u00e1 A., Vargov\u00e1 K.S. Analysis of 5-azacytidine resistance models reveals a set of targetable pathways. Cells. 2022;11:223.", "ArticleIdList": ["PMC8774143", "35053339"]}, {"Citation": "Hussain S., Tulsyan S., Dar S.A., Sisodiya S., Abiha U., Kumar R., Mishra B.N., Haque S. Role of epigenetics in carcinogenesis: recent advancements in anticancer therapy. Semin. Cancer Biol. 2022;83:441\u2013451. doi: 10.1016/j.semcancer.2021.06.023.", "ArticleIdList": ["10.1016/j.semcancer.2021.06.023", "34182144"]}, {"Citation": "S. Tasneem, M.M. Alam, M. Amir, M. Akhter, S. Parvez, G. Verma, L.M. Nainwal, A. Equbal, T. Anwer, M. Shaquiquzzaman, Heterocyclic moieties as HDAC inhibitors: role in cancer therapeutics, Mini-Rev. Med. Chem. 22 (n.d.) 1648\u20131706.", "ArticleIdList": ["34939540"]}, {"Citation": "Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of \u03b3-H2AX foci. Mol. Cancer Therapeut. 2006;5:1967\u20131974. doi: 10.1158/1535-7163.MCT-06-0022.", "ArticleIdList": ["10.1158/1535-7163.MCT-06-0022", "16928817"]}, {"Citation": "Pitts T.M., Morrow M., Kaufman S.A., Tentler J.J., Eckhardt S.G. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol. Cancer Therapeut. 2009;8:342\u2013349. doi: 10.1158/1535-7163.MCT-08-0534.", "ArticleIdList": ["10.1158/1535-7163.MCT-08-0534", "PMC2813767", "19174560"]}, {"Citation": "Bruzzese F., Rocco M., Castelli S., Di Gennaro E., Desideri A., Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol. Cancer Therapeut. 2009;8:3075\u20133087. doi: 10.1158/1535-7163.MCT-09-0254.", "ArticleIdList": ["10.1158/1535-7163.MCT-09-0254", "19887547"]}, {"Citation": "Bouyahya A., Mechchate H., Oumeslakht L., Zeouk I., Aboulaghras S., Balahbib A., Zengin G., Kamal M.A., Gallo M., Montesano D. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022;12:367.", "ArticleIdList": ["PMC8945214", "35327559"]}, {"Citation": "El Omari N., Bakrim S., Bakha M., Lorenzo J.M., Rebezov M., Shariati M.A., Aboulaghras S., Balahbib A., Khayrullin M., Bouyahya A. Natural bioactive compounds targeting epigenetic pathways in cancer: a review on alkaloids, terpenoids, quinones, and isothiocyanates. Nutrients. 2021;13:3714.", "ArticleIdList": ["PMC8621755", "34835969"]}, {"Citation": "Miranda Furtado C.L., Dos Santos Luciano M.C., Silva Santos R.D., Furtado G.P., Moraes M.O., Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14:1164\u20131176.", "ArticleIdList": ["PMC6791710", "31282279"]}, {"Citation": "Mohammad H.P., Barbash O., Creasy C.L. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat. Med. 2019;25:403\u2013418.", "ArticleIdList": ["30842676"]}, {"Citation": "Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005;37:391\u2013400.", "ArticleIdList": ["15765097"]}, {"Citation": "Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262\u20131266.", "ArticleIdList": ["15988529"]}, {"Citation": "Prachayasittikul V., Prathipati P., Pratiwi R., Phanus-Umporn C., Malik A.A., Schaduangrat N., Seenprachawong K., Wongchitrat P., Supokawej A., Prachayasittikul V. Exploring the epigenetic drug discovery landscape. Expet Opin. Drug Discov. 2017;12:345\u2013362.", "ArticleIdList": ["28276705"]}, {"Citation": "Xhemalce B., Dawson M.A., Bannister A.J. Histone modifications, rev. Cell Biol. Mol. Med. 2006;1-16"}, {"Citation": "Narita T., Weinert B.T., Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat. Rev. Mol. Cell Biol. 2019;20:156\u2013174.", "ArticleIdList": ["30467427"]}, {"Citation": "Marmorstein R. Structure of histone acetyltransferases. J. Mol. Biol. 2001;311:433\u2013444.", "ArticleIdList": ["11492997"]}, {"Citation": "Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834\u2013840.", "ArticleIdList": ["19608861"]}, {"Citation": "Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 2010;62:18\u201334.", "ArticleIdList": ["20219679"]}, {"Citation": "Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 2007;1:19\u201325.", "ArticleIdList": ["PMC5543853", "19383284"]}, {"Citation": "Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177\u2013189.", "ArticleIdList": ["15042618"]}, {"Citation": "Wilson A.J., Byun D.-S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006;281:13548\u201313558.", "ArticleIdList": ["16533812"]}, {"Citation": "Choi J.-H., Kwon H.J., Yoon B.-I., Kim J.-H., Han S.U., Joo H.J., Kim D.-Y. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 2001;92:1300\u20131304.", "ArticleIdList": ["PMC5926683", "11749695"]}, {"Citation": "Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., Hamaguchi M., Hara Y., Kobayashi S., Iwase H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat. 2005;94:11\u201316.", "ArticleIdList": ["16172792"]}, {"Citation": "Zhu P., Martin E., Mengwasser J., Schlag P., Janssen K.-P., G\u00f6ttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455\u2013463.", "ArticleIdList": ["15144953"]}, {"Citation": "Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., Raju G.C., Hooi S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21 Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12:395\u2013404.", "ArticleIdList": ["15665816"]}, {"Citation": "Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., Lee S.H., Park W.S., Yoo N.J., Lee J.Y. Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis. 2005;113:264\u2013268.", "ArticleIdList": ["15865607"]}, {"Citation": "Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S., Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 2004;10:6962\u20136968.", "ArticleIdList": ["15501975"]}, {"Citation": "Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., Caballero R., Alaminos M., Setien F., Paz M.F. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006;38:566\u2013569.", "ArticleIdList": ["16642021"]}, {"Citation": "Zimmermann S., Kiefer F., Prudenziati M., Spiller C., Hansen J., Floss T., Wurst W., Minucci S., G\u00f6ttlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 2007;67:9047\u20139054.", "ArticleIdList": ["17909008"]}, {"Citation": "Draney C., Austin M.C., Leifer A.H., Smith C.J., Kener K.B., Aitken T.J., Hess K.H., Haines A.C., Lett L.A., Hernandez-Carretero A. HDAC1 overexpression enhances \u03b2-cell proliferation by down-regulating Cdkn1b/p27. Biochem. J. 2018;475:3997\u20134010.", "ArticleIdList": ["30322885"]}, {"Citation": "Bouyahya A., El Hachlafi N., Aanniz T., Bourais I., Mechchate H., Benali T., Shariati M.A., Burkov P., Lorenzo J.M., Wilairatana P. Natural bioactive compounds targeting histone deacetylases in human cancers: recent updates. Molecules. 2022;27:2568.", "ArticleIdList": ["PMC9027183", "35458763"]}, {"Citation": "Kumagai T., Wakimoto N., Yin D., Gery S., Kawamata N., Takai N., Komatsu N., Chumakov A., Imai Y., Koeffler H.P. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer. 2007;121:656\u2013665. doi: 10.1002/ijc.22558.", "ArticleIdList": ["10.1002/ijc.22558", "17417771"]}, {"Citation": "Di Gennaro E., Bruzzese F., Pepe S., Leone A., Delrio P., Subbarayan P., Avallone A., Budillon A. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed. Cancer Biol. Ther. 2009;8:782\u2013791. doi: 10.4161/cbt.8.9.8118.", "ArticleIdList": ["10.4161/cbt.8.9.8118", "19270508"]}, {"Citation": "Di Gennaro E., Piro G., Chianese M.I., Franco R., Cintio A.D., Moccia T., Luciano A., de Ruggiero I., Bruzzese F., Avallone A., Arra C., Budillon A. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br. J. Cancer. 2010;103:1680\u20131691. doi: 10.1038/sj.bjc.6605969.", "ArticleIdList": ["10.1038/sj.bjc.6605969", "PMC2994231", "21045833"]}, {"Citation": "Bruzzese F., Leone A., Rocco M., Carbone C., Piro G., Caraglia M., Di Gennaro E., Budillon A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 2011;226:2378\u20132390. doi: 10.1002/jcp.22574.", "ArticleIdList": ["10.1002/jcp.22574", "21660961"]}, {"Citation": "Kwak T.W., Kim D.H., Chung C.-W., Lee H.M., Kim C.H., Jeong Y.-I., Kang D.H. Synergistic anticancer effects of vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells. Evid. Based Complement. Alternat. Med. 2013;2013:1\u201311. doi: 10.1155/2013/185158.", "ArticleIdList": ["10.1155/2013/185158", "PMC3706064", "23864881"]}, {"Citation": "Kwak T.W., Kim D.H., Jeong Y.-I., Kang D.H. Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells. J. Nanobiotechnol. 2015;13:60. doi: 10.1186/s12951-015-0122-4.", "ArticleIdList": ["10.1186/s12951-015-0122-4", "PMC4583727", "26410576"]}, {"Citation": "Campbell R.A., Sanchez E., Steinberg J., Shalitin D., Li Z.-W., Chen H., Berenson J.R. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur. J. Haematol. 2010;84:201\u2013211. doi: 10.1111/j.1600-0609.2009.01384.x.", "ArticleIdList": ["10.1111/j.1600-0609.2009.01384.x", "19929977"]}, {"Citation": "Ma X., Liu J., Wu J., Yan X., Wu P., Liu Y., Li S., Tian Y., Cao Y., Chen G., Meng L., Xu G., Wang S., Lu Y., Ma D., Zhou J. Synergistic killing effect between vorinostat and target of CD146 in malignant cells. Clin. Cancer Res. 2010;16:5165\u20135176. doi: 10.1158/1078-0432.CCR-09-3174.", "ArticleIdList": ["10.1158/1078-0432.CCR-09-3174", "20884621"]}, {"Citation": "Hrzenjak A., Moinfar F., Kremser M.-L., Strohmeier B., Petru E., Zatloukal K., Denk H. 2010. Histone Deacetylase Inhibitor Vorinostat Suppresses the Growth of Uterine Sarcomas in Vitro and in Vivo.", "ArticleIdList": ["PMC2843655", "20202195"]}, {"Citation": "Kahali S., Sarcar B., Fang B., Williams E.S., Koomen J.M., Tofilon P.J., Chinnaiyan P. Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia. 2010;12:80\u201386. doi: 10.1593/neo.91422.", "ArticleIdList": ["10.1593/neo.91422", "PMC2805886", "20072656"]}, {"Citation": "Mahalingam D., Medina E.C., Esquivel J.A., Espitia C.M., Smith S., Oberheu K., Swords R., Kelly K.R., Mita M.M., Mita A.C., Carew J.S., Giles F.J., Nawrocki S.T. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 2010;16:141\u2013153. doi: 10.1158/1078-0432.CCR-09-1385.", "ArticleIdList": ["10.1158/1078-0432.CCR-09-1385", "20028765"]}, {"Citation": "Mueller S., Yang X., Sottero T.L., Gragg A., Prasad G., Polley M.-Y., Weiss W.A., Matthay K.K., Davidoff A.M., DuBois S.G., Haas-Kogan D.A. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011;306:223\u2013229. doi: 10.1016/j.canlet.2011.03.010.", "ArticleIdList": ["10.1016/j.canlet.2011.03.010", "PMC3244077", "21497989"]}, {"Citation": "Kim D.R., Park M.-Y., Lee C.-S., Shim S.-H., Yoon H.-I., Lee J.H., Sung M.-W., Kim Y.-S., Lee C.-T. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther. 2011;18:467\u2013477. doi: 10.1038/cgt.2011.11.", "ArticleIdList": ["10.1038/cgt.2011.11", "21455254"]}, {"Citation": "Sarfstein R., Bruchim I., Fishman A., Werner H. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One. 2011;6 doi: 10.1371/journal.pone.0024468.", "ArticleIdList": ["10.1371/journal.pone.0024468", "PMC3169604", "21931726"]}, {"Citation": "Xargay-Torrent S., L\u00f3pez-Guerra M., Saborit-Villarroya I., Rosich L., Campo E., Rou\u00e9 G., Colomer D. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin. Cancer Res. 2011;17:3956\u20133968. doi: 10.1158/1078-0432.CCR-10-3412.", "ArticleIdList": ["10.1158/1078-0432.CCR-10-3412", "21652541"]}, {"Citation": "Bellarosa D., Bressan A., Bigioni M., Parlani M., Maggi C.A., Binaschi M. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int. J. Oncol. 2012;41:1486\u20131494. doi: 10.3892/ijo.2012.1551.", "ArticleIdList": ["10.3892/ijo.2012.1551", "22797667"]}, {"Citation": "Phillip C.J., Giardina C.K., Bilir B., Cutler D.J., Lai Y.-H., Kucuk O., Moreno C.S. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer. 2012;12:145. doi: 10.1186/1471-2407-12-145.", "ArticleIdList": ["10.1186/1471-2407-12-145", "PMC3472186", "22494660"]}, {"Citation": "Kurundkar D., Srivastava R.K., Chaudhary S.C., Ballestas M.E., Kopelovich L., Elmets C.A., Athar M. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol. Appl. Pharmacol. 2013;266:233\u2013244. doi: 10.1016/j.taap.2012.11.002.", "ArticleIdList": ["10.1016/j.taap.2012.11.002", "PMC3534787", "23147569"]}, {"Citation": "Bergad\u00e0 L., Sorolla A., Yeramian A., Eritja N., Mirantes C., Matias-Guiu X., Dolcet X. Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells. Mol. Oncol. 2013;7:763\u2013775. doi: 10.1016/j.molonc.2013.03.003.", "ArticleIdList": ["10.1016/j.molonc.2013.03.003", "PMC5528433", "23590818"]}, {"Citation": "Ge Z., Da Y., Xue Z., Zhang K., Zhuang H., Peng M., Li Y., Li W., Simard A., Hao J., Yao Z., Zhang R. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp. Neurol. 2013;241:56\u201366. doi: 10.1016/j.expneurol.2012.12.006.", "ArticleIdList": ["10.1016/j.expneurol.2012.12.006", "23261766"]}, {"Citation": "Muscal J.A., Scorsone K.A., Zhang L., Ecsedy J.A., Berg S.L. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest. N. Drugs. 2013;31:39\u201345. doi: 10.1007/s10637-012-9831-9.", "ArticleIdList": ["10.1007/s10637-012-9831-9", "PMC3655801", "22669335"]}, {"Citation": "Niegisch G., Knievel J., Koch A., Hader C., Fischer U., Albers P., Schulz W.A. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol. Semin. Orig. Investig. 2013;31:1770\u20131779. doi: 10.1016/j.urolonc.2012.06.015.", "ArticleIdList": ["10.1016/j.urolonc.2012.06.015", "22944197"]}, {"Citation": "Stark K., Burger A., Wu J., Shelton P., Polin L., Li J. Reactivation of estrogen receptor \u03b1 by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. PLoS One. 2013;8 doi: 10.1371/journal.pone.0074525.", "ArticleIdList": ["10.1371/journal.pone.0074525", "PMC3772827", "24058584"]}, {"Citation": "Tran K., Risingsong R., Royce D.B., Williams C.R., Sporn M.B., Pioli P.A., Gediya L.K., Njar V.C., Liby K.T. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis. 2013;34:199\u2013210. doi: 10.1093/carcin/bgs319.", "ArticleIdList": ["10.1093/carcin/bgs319", "PMC3534195", "23042302"]}, {"Citation": "Wilson P.M., LaBonte M.J., Martin S.C., Kuwahara S.T., El-Khoueiry A., Lenz H.-J., Ladner R.D. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest. N. Drugs. 2013;31:845\u2013857. doi: 10.1007/s10637-012-9914-7.", "ArticleIdList": ["10.1007/s10637-012-9914-7", "23299388"]}, {"Citation": "Lin W.-H., Yeh T.-K., Jiaang W.-T., Yen K.-J., Chen C.-H., Huang C.-T., Yen S.-C., Hsieh S.-Y., Chou L.-H., Chen C.-P., Chiu C.-H., Kao L.-C., Chao Y.-S., Chen C.-T., Hsu J.T.-A. Evaluation of the antitumor effects of bpr1j-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. PLoS One. 2014;9 doi: 10.1371/journal.pone.0083160.", "ArticleIdList": ["10.1371/journal.pone.0083160", "PMC3885398", "24416160"]}, {"Citation": "Hutt D.M., Roth D.M., Vignaud H., Cullin C., Bouchecareilh M. The histone deacetylase inhibitor, vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One. 2014;9 doi: 10.1371/journal.pone.0106224.", "ArticleIdList": ["10.1371/journal.pone.0106224", "PMC4148404", "25166596"]}, {"Citation": "Lu K., Chen N., Zhou X., Ge X., Feng L., Li P., Li X., Geng L., Wang X. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells. Biochem. Biophys. Res. Commun. 2015;464:292\u2013298. doi: 10.1016/j.bbrc.2015.06.145.", "ArticleIdList": ["10.1016/j.bbrc.2015.06.145", "26116769"]}, {"Citation": "Fern\u00e1ndez-Rodr\u00edguez C., Salar A., Navarro A., Gimeno E., Pairet S., Camacho L., Ferraro M., Serrano S., Besses C., Bellosillo B., Sanchez-Gonzalez B. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells, Leuk. Lymphoma. 2016;57:692\u2013699. doi: 10.3109/10428194.2015.1063143.", "ArticleIdList": ["10.3109/10428194.2015.1063143", "26084206"]}, {"Citation": "Pan C.-H., Chang Y.-F., Lee M.-S., Wen B.-C., Ko J.-C., Liang S.-K., Liang M.-C. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer. 2016;16:857. doi: 10.1186/s12885-016-2888-7.", "ArticleIdList": ["10.1186/s12885-016-2888-7", "PMC5100277", "27821078"]}, {"Citation": "Xue K., Gu J.J., Zhang Q., Mavis C., Hernandez-Ilizaliturri F.J., Czuczman M.S., Guo Y. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J. Cancer Res. Clin. Oncol. 2016;142:379\u2013387. doi: 10.1007/s00432-015-2026-y.", "ArticleIdList": ["10.1007/s00432-015-2026-y", "26314218"]}, {"Citation": "Rompicharla S.V.K., Trivedi P., Kumari P., Muddineti O.S., Theegalapalli S., Ghosh B., Biswas S. Evaluation of anti-tumor efficacy of vorinostat encapsulated self-assembled polymeric micelles in solid tumors. AAPS PharmSciTech. 2018;19:3141\u20133151. doi: 10.1208/s12249-018-1149-2.", "ArticleIdList": ["10.1208/s12249-018-1149-2", "30132129"]}, {"Citation": "Liu S., Zhang K., Zhu Q., Shen Q., Zhang Q., Yu J., Chen Y., Lu W. Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro. Bioorg. Med. Chem. 2019;27:1405\u20131413. doi: 10.1016/j.bmc.2019.02.046.", "ArticleIdList": ["10.1016/j.bmc.2019.02.046", "30819618"]}, {"Citation": "Park S., Kim D., Kim M., Lee J., Rho J., Jeong S., Choi E., Kim C., Hwang J. Vorinostat enhances gefitinib-induced cell death through reactive oxygen species-dependent cleavage of HSP90 and its clients in non-small cell lung cancer with the EGFR mutation. Oncol. Rep. 2018 doi: 10.3892/or.2018.6814.", "ArticleIdList": ["10.3892/or.2018.6814", "30365122"]}, {"Citation": "Piro G., Roca M.S., Bruzzese F., Carbone C., Iannelli F., Leone A., Volpe M.G., Budillon A., Di Gennaro E. Vorinostat potentiates 5-fluorouracil/cisplatin combination by inhibiting chemotherapy-induced EGFR nuclear translocation and increasing cisplatin uptake. Mol. Cancer Therapeut. 2019;18:1405\u20131417. doi: 10.1158/1535-7163.MCT-18-1117.", "ArticleIdList": ["10.1158/1535-7163.MCT-18-1117", "31189612"]}, {"Citation": "Eto S., Saeki K., Yoshitake R., Yoshimoto S., Shinada M., Ikeda N., Kamoto S., Tanaka Y., Kato D., Maeda S., Tsuboi M., Chambers J., Uchida K., Nishimura R., Nakagawa T. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One. 2019;14 doi: 10.1371/journal.pone.0218382.", "ArticleIdList": ["10.1371/journal.pone.0218382", "PMC6576781", "31206526"]}, {"Citation": "Laengle J., Kabiljo J., Hunter L., Homola J., Prodinger S., Egger G., Bergmann M. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis. J. Immunother. Cancer. 2020;8 doi: 10.1136/jitc-2019-000195.", "ArticleIdList": ["10.1136/jitc-2019-000195", "PMC7057438", "31940587"]}, {"Citation": "Tu B., He Y., Chen B., Wang Y., Gao Y., Shi M., Liu T., Asrorov A.M., Huang Y. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomater. Sci. 2020;8:7166\u20137176. doi: 10.1039/D0BM01516D.", "ArticleIdList": ["10.1039/D0BM01516D", "33169732"]}, {"Citation": "Xia C., He Z., Cai Y., Liang S. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells. Eur. J. Pharmacol. 2020;875 doi: 10.1016/j.ejphar.2020.173057.", "ArticleIdList": ["10.1016/j.ejphar.2020.173057", "32135122"]}, {"Citation": "Zhang Y., Huntington K. Abstract 4898: imipridones and EZH2 inhibitors induce similar changes in cytokines and regulated genes in GBM and DMG while vorinostat potentiates anti-tumor efficacy despite variability in cytokine profiles. Cancer Research | American Association for Cancer Research (2023) 2023 https://aacrjournals.org/cancerres/article/83/7_Supplement/4898/722331 4898."}, {"Citation": "Li Z., Li Z. Glucose regulated protein 78: a critical link between tumor microenvironment and cancer hallmarks. Biochim. Biophys. Acta BBA - Rev. Cancer. 2012;1826:13\u201322. doi: 10.1016/j.bbcan.2012.02.001.", "ArticleIdList": ["10.1016/j.bbcan.2012.02.001", "22426159"]}, {"Citation": "Liu C., Zheng S., Wang Z., Wang S., Wang X., Yang L., Xu H., Cao Z., Feng X., Xue Q., Wang Y., Sun N., He J. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 2022;42:828\u2013847. doi: 10.1002/cac2.12327.", "ArticleIdList": ["10.1002/cac2.12327", "PMC9456691", "35811500"]}, {"Citation": "Song M., Chen X., Wang L., Zhang Y. Future of anti-PD-1/PD-L1 applications: combinations with other therapeutic regimens. Chin. J. Cancer Res. 2018;30:157\u2013172. doi: 10.21147/j.issn.1000-9604.2018.02.01.", "ArticleIdList": ["10.21147/j.issn.1000-9604.2018.02.01", "PMC5953954", "29861603"]}, {"Citation": "Jorgovanovic D., Song M., Wang L., Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 2020;8:49. doi: 10.1186/s40364-020-00228-x.", "ArticleIdList": ["10.1186/s40364-020-00228-x", "PMC7526126", "33005420"]}, {"Citation": "Escors D., Gato-Ca\u00f1as M., Zuazo M., Arasanz H., Garc\u00eda-Granda M.J., Vera R., Kochan G. The intracellular signalosome of PD-L1 in cancer cells, Signal Transduct. Target. Ther. 2018;3:1\u20139. doi: 10.1038/s41392-018-0022-9.", "ArticleIdList": ["10.1038/s41392-018-0022-9", "PMC6160488", "30275987"]}, {"Citation": "Elbadawy M., Abugomaa A., Yamawaki H., Usui T., Sasaki K. Development of prostate cancer organoid culture models in basic medicine and translational research. Cancers. 2020;12:777. doi: 10.3390/cancers12040777.", "ArticleIdList": ["10.3390/cancers12040777", "PMC7226333", "32218271"]}, {"Citation": "Reebye V., Querol Cano L., Lavery D.N., Brooke G.N., Powell S.M., Chotai D., Walker M.M., Whitaker H.C., Wait R., Hurst H.C., Bevan C.L. Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol. Endocrinol. 2012;26:1694\u20131706. doi: 10.1210/me.2012-1056.", "ArticleIdList": ["10.1210/me.2012-1056", "PMC5416955", "22899854"]}, {"Citation": "Condelli V., Crispo F., Pietrafesa M., Lettini G., Matassa D.S., Esposito F., Landriscina M., Maddalena F. HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy. Cells. 2019;8:532. doi: 10.3390/cells8060532.", "ArticleIdList": ["10.3390/cells8060532", "PMC6627532", "31163702"]}, {"Citation": "Rosati R., Chen B., Patki M., McFall T., Ou S., Heath E., Ratnam M., Qin Z. Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease HSP90 and the androgen receptor levels and inhibit viability in enzalutamide resistant C4-2 prostate cancer cells. Mol. Pharmacol. 2016 doi: 10.1124/mol.116.103416.", "ArticleIdList": ["10.1124/mol.116.103416", "PMC4998664", "27382012"]}, {"Citation": "Bouyahya A., El Allam A., Aboulaghras S., Bakrim S., El Menyiy N., Alshahrani M.M., Al Awadh A.A., Benali T., Lee L.-H., El Omari N., Goh K.W., Ming L.C., Mubarak M.S. Targeting mTOR as a cancer therapy: recent advances in natural bioactive compounds and immunotherapy. Cancers. 2022;14:5520. doi: 10.3390/cancers14225520.", "ArticleIdList": ["10.3390/cancers14225520", "PMC9688668", "36428613"]}, {"Citation": "Liby K.T., Yore M.M., Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer. 2007;7:357\u2013369. doi: 10.1038/nrc2129.", "ArticleIdList": ["10.1038/nrc2129", "17446857"]}, {"Citation": "Liby K.T., Sporn M.B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 2012;64:972\u20131003. doi: 10.1124/pr.111.004846.", "ArticleIdList": ["10.1124/pr.111.004846", "PMC3462991", "22966038"]}, {"Citation": "Honda T., Rounds B.V., Gribble G.W., Suh N., Wang Y., Sporn M.B. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg. Med. Chem. Lett. 1998;8:2711\u20132714. doi: 10.1016/S0960-894X(98)00479-X.", "ArticleIdList": ["10.1016/S0960-894X(98)00479-X", "9873608"]}, {"Citation": "Oua\u00efssi M., Silvy F., Loncle C., Ferraz da Silva D., Martins Abreu C., Martinez E., Berth\u00e9zene P., Cadra S., Le Treut Y.P., Hardwigsen J., Sastre B., Sielezneff I., Benkoel L., Delgrande J., Ouaissi A., Iovanna J., Lombardo D., Mas E. Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. PLoS One. 2014;9 doi: 10.1371/journal.pone.0108520.", "ArticleIdList": ["10.1371/journal.pone.0108520", "PMC4183483", "25275504"]}, {"Citation": "Chang T., Lian Z., Ma S., Liang Z., Ma X., Wen X., Wang Y., Liu R. Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH. Prostate. 2023;83:470\u2013486.", "ArticleIdList": ["36576015"]}, {"Citation": "Salama B.M., Helmy M.W., Fouad H., Shamaa M.M., Houssen M.E. The synergistic antitumor effect of decitabine and vorinostat combination on HepG2 human hepatocellular carcinoma cell line via epigenetic modulation of autophagy\u2013apoptosis molecular crosstalk. Curr. Issues Mol. Biol. 2023;45:5935\u20135949.", "ArticleIdList": ["PMC10378248", "37504291"]}, {"Citation": "Rezano A., Ridhayanti F., Rangkuti A.R., Gunawan T., Winarno G.N.A., Wijaya I. Cytotoxicity of simvastatin in human breast cancer MCF-7 and MDA-MB-231 cell lines. Asian Pac. J. Cancer Prev. 2021;22:33\u201342. doi: 10.31557/APJCP.2021.22.S1.33.", "ArticleIdList": ["10.31557/APJCP.2021.22.S1.33", "33576210"]}, {"Citation": "Lin X., Okuda T., Holzer A., Howell S.B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol. 2002;62:1154\u20131159. doi: 10.1124/mol.62.5.1154.", "ArticleIdList": ["10.1124/mol.62.5.1154", "12391279"]}, {"Citation": "Pan B., Yin S., Peng F., Liu C., Liang H., Su J., Hsiao W.W., Cai Y., Luo D., Xia C. Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. Eur. J. Pharmacol. 2021;908", "ArticleIdList": ["34331954"]}, {"Citation": "Mrakovcic M., Fr\u00f6hlich L.F. Molecular determinants of cancer therapy resistance to HDAC inhibitor-induced autophagy. Cancers. 2019;12:109.", "ArticleIdList": ["PMC7016854", "31906235"]}, {"Citation": "Chen J.-L., Jia X.-H., Xia X., Wu X., Xu Y.-N., Yuan G., Gu Z.-Y., Luo K.Q., Yuan M.-H., Jiang R. Codelivery of vorinostat and chloroquine by autophagy-inhibitory hollow ZrO2 nanoshells for synergistic combination chemotherapy. Chem. Eng. J. 2023;471"}, {"Citation": "Bordeaux Z.A., Reddy S.V., Lee K., Lu W., Choi J., Miller M., Roberts C., Pollizzi A., Kwatra S.G., Kwatra M.M. Differential response of mycosis fungoides cells to vorinostat. Int. J. Mol. Sci. 2023;24:8075.", "ArticleIdList": ["PMC10179468", "37175780"]}, {"Citation": "Maksimova V., Makus J., Popova V., Prus A., Usalka O., Trapeznikova E., Zhidkova E., Belitsky G., Yakubovskaya M., Kirsanov K. Histone methyltransferases as a new target for epigenetic action of vorinostat. Biochem. Mosc. 2023;88:968\u2013978.", "ArticleIdList": ["37751867"]}, {"Citation": "Ramalingam S.S., Parise R.A., Ramananthan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., Potter D.M., Argiris A.E., Zwiebel J.A., Egorin M.J., Belani C.P. Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 2007;13:3605\u20133610. doi: 10.1158/1078-0432.CCR-07-0162.", "ArticleIdList": ["10.1158/1078-0432.CCR-07-0162", "17510206"]}, {"Citation": "Traynor A.M., Dubey S., Eickhoff J., Kolesar J.M., Marcotte S.M., Hammes L.C., Hallahan C.M., Moore C.E., Zwiebel J., Schiller J.H. A phase II study of vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC) J. Clin. Oncol. 2007;25 18044\u201318044."}, {"Citation": "Blumenschein G.R., Kies M.S., Papadimitrakopoulou V.A., Lu C., Kumar A.J., Ricker J.L., Chiao J.H., Chen C., Frankel S.R. Phase II trial of the histone deacetylase inhibitor vorinostat (ZolinzaTM, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. N. Drugs. 2008;26:81\u201387. doi: 10.1007/s10637-007-9075-2.", "ArticleIdList": ["10.1007/s10637-007-9075-2", "17960324"]}, {"Citation": "Bradley D., Rathkopf D., Dunn R., Stadler W.M., Liu G., Smith D.C., Pili R., Zwiebel J., Scher H., Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (national cancer institute trial 6862): trial results and interleukin-6 analysis: a study by the department of defense prostate cancer clinical trial consortium and university of Chicago phase 2 consortium. Cancer. 2009;115:5541\u20135549. doi: 10.1002/cncr.24597.", "ArticleIdList": ["10.1002/cncr.24597", "PMC2917101", "19711464"]}, {"Citation": "Fujiwara Y., Yamamoto N., Yamada Y., Yamada K., Otsuki T., Kanazu S., Iwasa T., Hardwick J.S., Tamura T. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 2009;100:1728\u20131734. doi: 10.1111/j.1349-7006.2009.01237.x.", "ArticleIdList": ["10.1111/j.1349-7006.2009.01237.x", "19575752"]}, {"Citation": "Woyach J.A., Kloos R.T., Ringel M.D., Arbogast D., Collamore M., Zwiebel J.A., Grever M., Villalona-Calero M., Shah M.H. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 2009;94:164\u2013170. doi: 10.1210/jc.2008-1631.", "ArticleIdList": ["10.1210/jc.2008-1631", "PMC2630867", "18854394"]}, {"Citation": "Ree A.H., Dueland S., Folkvord S., Hole K.H., Seierstad T., Johansen M., Abrahamsen T.W., Flatmark K. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010;11:459\u2013464. doi: 10.1016/S1470-2045(10)70058-9.", "ArticleIdList": ["10.1016/S1470-2045(10)70058-9", "20378407"]}, {"Citation": "Stathis A., Hotte S.J., Chen E.X., Hirte H.W., Oza A.M., Moretto P., Webster S., Laughlin A., Stayner L.-A., McGill S., Wang L., Zhang W., Espinoza-Delgado I., Holleran J.L., Egorin M.J., Siu L.L. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-hodgkin\u2019s lymphomas. Clin. Cancer Res. 2011;17:1582\u20131590. doi: 10.1158/1078-0432.CCR-10-1893.", "ArticleIdList": ["10.1158/1078-0432.CCR-10-1893", "21278245"]}, {"Citation": "Munster P.N., Thurn K.T., Thomas S., Raha P., Lacevic M., Miller A., Melisko M., Ismail-Khan R., Rugo H., Moasser M., Minton S.E. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer. 2011;104:1828\u20131835. doi: 10.1038/bjc.2011.156.", "ArticleIdList": ["10.1038/bjc.2011.156", "PMC3111195", "21559012"]}, {"Citation": "Dummer R., Beyer M., Hymes K., Epping M.T., Bernards R., Steinhoff M., Sterry W., Kerl H., Heath K., Ahern J.D., Hardwick J.S., Garcia-Vargas J., Baumann K., Rizvi S., Frankel S.R., Whittaker S.J., Assaf C. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk. Lymphoma. 2012;53:1501\u20131508. doi: 10.3109/10428194.2012.656625.", "ArticleIdList": ["10.3109/10428194.2012.656625", "22239668"]}, {"Citation": "Fakih M.G., Groman A., McMahon J., Wilding G., Muindi J.R. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother. Pharmacol. 2012;69:743\u2013751. doi: 10.1007/s00280-011-1762-1.", "ArticleIdList": ["10.1007/s00280-011-1762-1", "22020318"]}, {"Citation": "Millward M., Price T., Townsend A., Sweeney C., Spencer A., Sukumaran S., Longenecker A., Lee L., Lay A., Sharma G., Gemmill R.M., Drabkin H.A., Lloyd G.K., Neuteboom S.T.C., McConkey D.J., Palladino M.A., Spear M.A. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. N. Drugs. 2012;30:2303\u20132317. doi: 10.1007/s10637-011-9766-6.", "ArticleIdList": ["10.1007/s10637-011-9766-6", "22080430"]}, {"Citation": "Witt O., Milde T., Deubzer H., Oehme I., Witt R., Kulozik A., Eisenmenger A., Abel U., Karapanagiotou-Schenkel I. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia, klin. P\u00e4diatr. 2012;224:398\u2013403. doi: 10.1055/s-0032-1323692.", "ArticleIdList": ["10.1055/s-0032-1323692", "22915450"]}, {"Citation": "Doi T., Hamaguchi T., Shirao K., Chin K., Hatake K., Noguchi K., Otsuki T., Mehta A., Ohtsu A. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int. J. Clin. Oncol. 2013;18:87\u201395. doi: 10.1007/s10147-011-0348-6.", "ArticleIdList": ["10.1007/s10147-011-0348-6", "22234637"]}, {"Citation": "Tu Y., Hershman D.L., Bhalla K., Fiskus W., Pellegrino C.M., Andreopoulou E., Makower D., Kalinsky K., Fehn K., Fineberg S., Negassa A., Montgomery L.L., Wiechmann L.S., Alpaugh R.K., Huang M., Sparano J.A. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res. Treat. 2014;146:145\u2013152. doi: 10.1007/s10549-014-3008-5.", "ArticleIdList": ["10.1007/s10549-014-3008-5", "24903226"]}, {"Citation": "Mahalingam D., Mita M., Sarantopoulos J., Wood L., Amaravadi R.K., Davis L.E., Mita A.C., Curiel T.J., Espitia C.M., Nawrocki S.T., Giles F.J., Carew J.S. Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014;10:1403\u20131414. doi: 10.4161/auto.29231.", "ArticleIdList": ["10.4161/auto.29231", "PMC4203517", "24991835"]}, {"Citation": "Patel S., Hurez V., Nawrocki S.T., Goros M., Michalek J., Sarantopoulos J., Curiel T., Mahalingam D. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. Oncotarget. 2016;7:59087\u201359097. doi: 10.18632/oncotarget.10824.", "ArticleIdList": ["10.18632/oncotarget.10824", "PMC5312297", "27463016"]}, {"Citation": "Pili R., Liu G., Chintala S., Verheul H., Rehman S., Attwood K., Lodge M.A., Wahl R., Martin J.I., Miles K.M., Paesante S., Adelaiye R., Godoy A., King S., Zwiebel J., Carducci M.A. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. Br. J. Cancer. 2017;116:874\u2013883. doi: 10.1038/bjc.2017.33.", "ArticleIdList": ["10.1038/bjc.2017.33", "PMC5379145", "28222071"]}, {"Citation": "Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 2007;74:659\u2013671. doi: 10.1016/j.bcp.2007.04.007.", "ArticleIdList": ["10.1016/j.bcp.2007.04.007", "17498667"]}, {"Citation": "Han H.S., Arun B.K., Kaufman B., Wildiers H., Friedlander M., Ayoub J.P., Puhalla S.L., Bach B.A., Kundu M.G., Khandelwal N., Feng D., Bhattacharya S., Maag D., Ratajczak C.K., Di\u00e9ras V. Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. Ann. Oncol. 2022;33:299\u2013309. doi: 10.1016/j.annonc.2021.11.018.", "ArticleIdList": ["10.1016/j.annonc.2021.11.018", "34861374"]}, {"Citation": "Reck M., Shankar G., Lee A., Coleman S., McCleland M., Papadimitrakopoulou V.A., Socinski M.A., Sandler A. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expet Rev. Respir. Med. 2020;14:125\u2013136. doi: 10.1080/17476348.2020.1701439.", "ArticleIdList": ["10.1080/17476348.2020.1701439", "31829747"]}, {"Citation": "Scheuplein R.J., Shoaf S.E., Brown R.N. 1990. Role of Pharmacokinetics in Safety Evaluation and Regulatory Considerations.", "ArticleIdList": ["2188568"]}, {"Citation": "Buffet C., Wassermann J., Hecht F., Leenhardt L., Dupuy C., Groussin L., Lussey-Lepoutre C. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr. Relat. Cancer. 2020;27:R113\u2013R132. doi: 10.1530/ERC-19-0491.", "ArticleIdList": ["10.1530/ERC-19-0491", "32191916"]}, {"Citation": "Jin Y., Van Nostrand D., Cheng L., Liu M., Chen L. Radioiodine refractory differentiated thyroid cancer. Crit. Rev. Oncol. Hematol. 2018;125:111\u2013120. doi: 10.1016/j.critrevonc.2018.03.012.", "ArticleIdList": ["10.1016/j.critrevonc.2018.03.012", "29650270"]}, {"Citation": "Cameron M.G., Kersten C., Vistad I., van Helvoirt R., Weyde K., Undseth C., Mjaaland I., Skovlund E., Foss\u00e5 S.D., Guren M.G. Palliative pelvic radiotherapy for symptomatic incurable prostate cancer \u2013 a prospective multicenter study. Radiother. Oncol. 2015;115:314\u2013320. doi: 10.1016/j.radonc.2015.05.021.", "ArticleIdList": ["10.1016/j.radonc.2015.05.021", "26091575"]}, {"Citation": "Yu Y., Wang T., Wu Y., Zhou Y., Jiang Y., Zhang L. Effect of elicitors on the metabolites in the suspension cell culture of Salvia miltiorrhiza Bunge. Physiol. Mol. Biol. Plants. 2019;25:229\u2013242.", "ArticleIdList": ["PMC6352533", "30804645"]}, {"Citation": "Chen C., Wang Z., Ding Y., Wang L., Wang S., Wang H., Qin Y. DNA methylation: from cancer biology to clinical perspectives. Front. Biosci.-Landmark. 2022;27:326. doi: 10.31083/j.fbl2712326.", "ArticleIdList": ["10.31083/j.fbl2712326", "36624943"]}, {"Citation": "Mohd Idris R.A., Mussa A., Ahmad S., Al-Hatamleh M.A.I., Hassan R., Tengku Din T.A.D.A.A., Wan Abdul Rahman W.F., Lazim N.M., Boer J.C., Plebanski M., Mohamud R. The effects of tamoxifen on tolerogenic cells in cancer. Biology. 2022;11:1225. doi: 10.3390/biology11081225.", "ArticleIdList": ["10.3390/biology11081225", "PMC9405160", "36009853"]}, {"Citation": "Jurutka P.W., di Martino O., Reshi S., Mallick S., Sabir Z.L., Staniszewski L.J.P., Warda A., Maiorella E.L., Minasian A., Davidson J., Ibrahim S.J., Raban S., Haddad D., Khamisi M., Suban S.L., Dawson B.J., Candia R., Ziller J.W., Lee M.-Y., Liu C., Liu W., Marshall P.A., Welch J.S., Wagner C.E. Modeling, synthesis, and biological evaluation of potential retinoid-X-receptor (RXR) elective agonists: analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic acid (NEt-4IB) Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms222212371.", "ArticleIdList": ["10.3390/ijms222212371", "PMC8624485", "34830251"]}, {"Citation": "Miles S.A., Conrad S.M., Alves R.G., Jeronimo S.M., Mosser D.M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 2005;201:747\u2013754.", "ArticleIdList": ["PMC1351290", "15753208"]}, {"Citation": "Thibaudeau T.A., Smith D.M. A practical review of proteasome pharmacology. Pharmacol. Rev. 2019;71:170\u2013197. doi: 10.1124/pr.117.015370.", "ArticleIdList": ["10.1124/pr.117.015370", "PMC6423620", "30867233"]}, {"Citation": "Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90. J. Biol. Chem. 2005;280:26729\u201326734. doi: 10.1074/jbc.C500186200.", "ArticleIdList": ["10.1074/jbc.C500186200", "15937340"]}, {"Citation": "Zamame Ramirez J.A., Romagnoli G.G., Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. Life Sci. 2021;265 doi: 10.1016/j.lfs.2020.118745.", "ArticleIdList": ["10.1016/j.lfs.2020.118745", "33186569"]}, {"Citation": "Piffoux M., Eriau E., Cassier P.A. Autophagy as a therapeutic target in pancreatic cancer. Br. J. Cancer. 2021;124:333\u2013344. doi: 10.1038/s41416-020-01039-5.", "ArticleIdList": ["10.1038/s41416-020-01039-5", "PMC7852577", "32929194"]}, {"Citation": "Jiang G.-M., Tan Y., Wang H., Peng L., Chen H.-T., Meng X.-J., Li L.-L., Liu Y., Li W.-F., Shan H. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol. Cancer. 2019;18:17. doi: 10.1186/s12943-019-0944-z.", "ArticleIdList": ["10.1186/s12943-019-0944-z", "PMC6345046", "30678689"]}, {"Citation": "Ramakrishnan R., Huang C., Cho H.-I., Lloyd M., Johnson J., Ren X., Altiok S., Sullivan D., Weber J., Celis E., Gabrilovich D.I. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012;72:5483\u20135493. doi: 10.1158/0008-5472.CAN-12-2236.", "ArticleIdList": ["10.1158/0008-5472.CAN-12-2236", "PMC4577568", "22942258"]}, {"Citation": "Cardones A., Banez L. VEGF inhibitors in cancer therapy. Curr. Pharmaceut. Des. 2006;12:387\u2013394. doi: 10.2174/138161206775201910.", "ArticleIdList": ["10.2174/138161206775201910", "16454752"]}, {"Citation": "Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69:11\u201316. doi: 10.1159/000088479.", "ArticleIdList": ["10.1159/000088479", "16301831"]}, {"Citation": "El Omari N., Bakrim S., Khalid A., Abdalla A.N., Almalki W.H., Lee L.-H., Ardianto C., Ming L.C., Bouyahya A. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses. Biomed. Pharmacother. 2023;164", "ArticleIdList": ["37224752"]}, {"Citation": "Bouyahya A., El Omari N., Bakha M., Aanniz T., El Menyiy N., El Hachlafi N., El Baaboua A., El-Shazly M., Alshahrani M.M., Al Awadh A.A. Pharmacological properties of trichostatin A, focusing on the anticancer potential: a comprehensive review. Pharmaceuticals. 2022;15:1235.", "ArticleIdList": ["PMC9612318", "36297347"]}, {"Citation": "Bouyahya A., Mechchate H., Benali T., Ghchime R., Charfi S., Balahbib A., Burkov P., Shariati M.A., Lorenzo J.M., Omari N.E. Health benefits and pharmacological properties of carvone. Biomolecules. 2021;11:1803.", "ArticleIdList": ["PMC8698960", "34944447"]}, {"Citation": "El Omari N., El Menyiy N., Zengin G., Goh B.H., Gallo M., Montesano D., Naviglio D., Bouyahya A. Anticancer and anti-inflammatory effects of tomentosin: cellular and molecular mechanisms. Separations. 2021;8:207."}, {"Citation": "Khorsandi K., Kianmehr Z., Hosseinmardi Z., Hosseinzadeh R. Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. Cancer Cell Int. 2020;20:18. doi: 10.1186/s12935-020-1100-y.", "ArticleIdList": ["10.1186/s12935-020-1100-y", "PMC6958578", "31956296"]}, {"Citation": "Zhang T., Ma L., Wu P., Li W., Li T., Gu R., Dan X., Li Z., Fan X., Xiao Z. Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non-small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway, Oncol. Rep. 2019 doi: 10.3892/or.2019.6976.", "ArticleIdList": ["10.3892/or.2019.6976", "30747218"]}, {"Citation": "Vafadar A., Shabaninejad Z., Movahedpour A., Fallahi F., Taghavipour M., Ghasemi Y., Akbari M., Shafiee A., Hajighadimi S., Moradizarmehri S., Razi E., Savardashtaki A., Mirzaei H. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci. 2020;10:32. doi: 10.1186/s13578-020-00397-0.", "ArticleIdList": ["10.1186/s13578-020-00397-0", "PMC7063794", "32175075"]}, {"Citation": "Reyes-Farias M., Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int. J. Mol. Sci. 2019;20:3177.", "ArticleIdList": ["PMC6651418", "31261749"]}]}], "History": [{"Year": "2024", "Month": "1", "Day": "21"}, {"Year": "2024", "Month": "6", "Day": "7"}, {"Year": "2024", "Month": "6", "Day": "13"}, {"Year": "2024", "Month": "7", "Day": "18", "Hour": "6", "Minute": "44"}, {"Year": "2024", "Month": "7", "Day": "18", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "7", "Day": "18", "Hour": "4", "Minute": "43"}, {"Year": "2024", "Month": "6", "Day": "18"}], "PublicationStatus": "epublish", "ArticleIdList": ["39021957", "PMC11253278", "10.1016/j.heliyon.2024.e33052", "S2405-8440(24)09083-2"]}}]}